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Abstract
It is known that cancer is caused by an accumulation of mutations
in DNA. Many genes have been associated with tumour
progression either through germline or somatic mutations, but
mutations in these genes by no means account for all instances of
the disease. The availability of the completed human genome
sequence and reduced costs of sequencing have allowed large-
scale screens to uncover genes that are somatically mutated in
cancer. In this issue, Chanock and colleagues present a screen of
91 breast cancers for somatic variants in a set of 21 genes.
Over recent years, kinase genes have received much
attention in this field because of their central role in many
cellular processes, especially cell growth and proliferation
[1-8]. Mutations in kinases have also been linked with cancer
progression and have proved to be a successful target for
therapeutic intervention. One such success was the
treatment of HER2/neu overexpressing metastatic breast
cancer with the anti-HER2/neu antibody trastuzumab
(Herceptin). Groups are now focusing their efforts on other
sets of genes to try to find new targets for cancer therapies.
Chanock and colleagues [9] chose their gene set on the
basis of either gene expression data, which they had
previously published [10,11], or a known association with
breast cancer. This is the first time that expression data has
been used to guide systematic resequencing studies. A total
of 87 somatic variants, spread across 16 genes, were
uncovered by this study. About one quarter of the variants are
in  TP53, with the remainder spread through the other 15
mutated genes. The authors point out that there could be a
proportion of rare SNPs in the reported set of ‘somatic’
variants because they did not have matched normal tissue for
every tumour; overall conclusions relative to prevalence and
pattern should therefore be drawn cautiously. The authors
highlight that they uncovered non-synonymous somatic
variants in genes that a recently published study by Sjöblom
and colleagues [12] failed to find any variants in. They believe
that the differing results may be due in part to the different
oestrogen receptor status of the breast tumours used by
each group because they have previously observed
differences in gene expression patterns between tumour
classes. This observation serves to highlight the value of
screening many different types of tumour.
Another unique point of this study is the sequencing of large
areas of non-coding (intronic and 5′ and 3′ flanking) DNA,
which has been largely avoided by other groups in favour of
targeting resources to coding and splice site sequencing.
Excluding non-coding regions could result in the overlooking
of variants that alter gene expression; however, determining
whether variants in non-coding regions provide a selective
advantage to these tumours will be problematic. In fact, trying
to discern which somatic variants have an active role in
cancer progression (driver mutations) and which do not
(passengers) is difficult even for coding variants. Some
groups have taken a statistical approach. Greenman and
colleagues [13] described methods to determine whether
driver mutations are present in a mutation data set, to
determine how many there are likely to be, and finally to give
an indication of which genes they are likely to be in. These
methods rely on screening for silent variants to obtain
estimates of the background mutation prevalence, indepen-
dent of selection. Comparing the observed to expected ratios
of synonymous:non-synonymous variants enables selection
pressures to be detected and estimated. Greenman and
colleagues then used domain-specific and gene-specific
methods to identify genes likely to be involved in tumour
progression. Sjöblom and colleagues [12] screened for non-
synonymous variants only, comparing the resulting gene-
specific prevalences with background estimates from other
studies to identify genes likely to be involved in tumour
progression. Alternatively, various bioinformatics methods
can be employed to give an indication of whether an amino
acid substitution is likely to damage protein function on the
basis of either conservation through species or whether or
not the amino acid change is conservative. The study by
Chanock and colleagues [9] favoured this type of analysis
(Miyata score) to indicate which substitutions are more likely
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to alter the protein structure and therefore be pathogenic.
However, each group did concur that most variants
uncovered through these large-scale screens are passengers
and only a minority actually confer a selective advantage on
the tumour. Ultimately, it is direct functional studies of genes
implicated by large-scale screening projects that will yield
conclusive proof of cancer gene status. This and other
studies have yielded a wealth of such targets, and the
ongoing work of these groups as well as the new Cancer
Genome Atlas project funded by the National Institutes of
Health are sure to provide many more.
Another interesting point raised by this group is the difficulty
of detecting heterozygous variants in DNA samples from
primary tissues because of their heterogeneous nature. They
point out that pre-screening, such as the temporal
temperature electrophoresis that was used on a limited set of
their samples, is impractical for high-throughput screens. This
problem could be tackled by developing software to improve
the detection of variants by using current sequencing
technologies. Alternatively, the new sequencing technologies,
which allow single molecules of DNA to be analysed, could
be a more attractive proposition. These new technologies
should also reduce the time and cost of large-scale
resequencing projects such that the sequencing of entire
cancer genomes should soon be feasible.
Large-scale sequencing strategies to uncover genes that are
somatically mutated in cancer are producing a wealth of such
data and promise to continue doing so. All of these studies
have given us greater insights into the complexity of cancer at
the molecular level. It is to be hoped that the combined effort
of all of the groups concerned should uncover some as yet
unknown genes or groups of genes amenable to therapeutic
intervention and build on previous successes to discover new
treatments for cancer.
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